Medication Prior Authorization Form
|
|
- Loren Nelson
- 6 years ago
- Views:
Transcription
1 Policy Number: 1041 FEIBA NF Novoeight Mononine NovoSeven RT RECOMBINATE BEBULIN HEMOFIL M Xyntha Profilnine SD Koate-DVI Obizur BeneFix Monoclate-P Alphanate RIXUBIS ADVATE HUMATE-P Corifact Helixate FS Wilate TRETTEN Kogenate FS AlphaNine SD RiaSTAP Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s) listed in this policy. Decisions for authorization are subject to all terms and conditions of the applicable benefit plan, including specific exclusions and limitations as well as applicable state and/or federal laws. Please review the benefit plan descriptions for details. We utilize a combination of MCG and internally developed evidence-based clinical guidelines to support our prior authorization work. All internally developed prior authorization guidelines follow a rigorous process including, but not limited to, review by clinical pharmacist, clinical nurse manager, Chief Medical Officer, independent 3 rd party physician review agency and WEA Trust s Medical Advisory Committee. Prior authorization guidelines are reviewed at least annually, or when there are significant labeling changes made by FDA or peer-reviewed clinical outcomes (via Cochrane or Hayes). INSTRUCTIONS: Please review section I and complete sections II, III, and IV (type or print clearly). Prescribers are asked to submit this form along with supporting clinical documentation to the WEA Trust for review. Submission of form does not guarantee approval. Submit preauthorization (PA) by fax to the WEA Trust at (608) or by mail to WEA Trust, Pharmacy Services Prior Authorization, PO Box 21538, Eagan MN
2 Page 2 Section I Approval Criteria I. Anti-inhibitor Coagulant Complex (FEIBA NF) A. Anti-inhibitor coagulant complex agents (FEIBA NF) are medically necessary to treat individuals with hemophilia A or B with inhibitors when the following criteria are met: i. Treatment of bleeding episodes OR ii. Peri-procedural operative management for surgical, invasive or interventional radiology procedures OR iii. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes B. Anti-inhibitor coagulant complex is not medically necessary when the above criteria are not met and for all other indications including, but not limited to treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation Factor VIII or coagulation Factor IX C. FEIBA NF (anti-inhibitor coagulant complex) has a black box warning for thrombotic and thromboembolic events, which have been reported during post marketing surveillance following infusion, particularly following the administration of high doses and/or in individuals with thrombotic risk factors II. Factor VIIa Recombinant (NovoSeven RT) A. Factor VIIa recombinant coagulation agents (NovoSeven RT) are medically necessary for the following: i. Treatment of bleeding episodes when the following criteria are met: 1. Individual has hemophilia A or B with inhibitors to Factor VIII or Factor IX OR 2. Individual has acquired hemophilia OR 3. Individual has congenital Factor VII deficiency OR ii. In the prevention of bleeding in surgical interventions or invasive procedures for the following: 1. Individual has hemophilia A or B with inhibitors to Factor VIII or Factor IX OR 2. Individual has acquired hemophilia OR 3. Individual has congenital Factor VII deficiency OR iii. To treat individuals with Glanzmann s thrombasthenia and a documented refractoriness to platelet transfusions with or without antibodies to platelets B. Recombinant coagulation Factor VIIa (NovoSeven RT) are not medically necessary when the above criteria are not met and for all other indications C. NovoSeven, NovoSeven RT [coagulation Factor VIIa (recombinant)] has a black box warning for serious arterial and venous thrombotic events following administration. Individuals should be monitored for signs and symptoms of activation of the coagulation system and for thrombosis III. factor (factor VIII) Human plasma-derived (HEMOFIL M, Koate-DVI, Monoclate-P) A. factor (Factor VIII) human plasma-derived agents (HEMOFIL M, Koate-DVI, Monoclate-P) is medically necessary for the following: i. Treatment of bleeding episodes in an individual with hemophilia A and factor VIII deficiency B. factor (Factor VIII) human plasma-derived agents (Koate-DVI, Monoclate-P) are medically necessary for the following: i. As peri-procedural management for surgical, invasive or interventional radiology procedures in an individual with hemophilia A and factor VIII deficiency C. factor (Factor VIII) human plasma-derived agents (HEMOFIL M, Koate-DVI, Monoclate-P) are not medically necessary when the above criteria are not met including, but not limited to treatment of individuals with von Willebrand disease (VWD) IV. factor (factor VIII) Recombinant (ADVATE, Helixate FS, Kogenate FS, Novoeight, RECOMBINATE, Xyntha) A. factor (Factor VIII) recombinant agents (ADVATE, Helixate FS, Kogenate FS, Novoeight, RECOMBINATE, Xyntha) are medically necessary for the following: i. For the treatment of bleeding episodes in an individual with hemophilia A and factor VIII deficiency OR ii. As peri-procedural management for surgical, invasive or interventional radiology procedures for an
3 Page 3 individual with hemophilia A and Factor VIII deficiency B. Factor VIII Recombinant (ADVATE, Helixate FS, Novoeight) is medically necessary as routine prophylaxis to prevent or reduce the frequency of bleeding episodes when the following criteria are met (i alone OR ii and iii): i. Individual has severe hemophilia A (defined as less than or equal to 1 International Unit per deciliter [IU/dL] or 1% endogenous Factor VIII) OR ii. Individual has mild to moderate hemophilia A (defined as endogenous Factor VIII less than or equal to 40 IU/dL [less than or equal to 40%], but greater than 1 IU) AND iii. When the individual has documented history of one of the following: 1. One or more episodes of spontaneous bleeding into joint OR 2. One or more episodes of spontaneous bleeding into the central nervous system OR 3. Four or more episodes of soft tissue bleeding in an eight week period C. Factor VIII Recombinant (Helixate FS, Kogenate FS) is medically necessary for the following: i. As routine prophylaxis for children (age 0-16 years) with hemophilia A and factor VIII deficiency to reduce the risk of joint damage in those without pre-existing joint damage D. Factor VIII Recombinant (Recombinate) is medically necessary for the following: i. As treatment of individuals with acquired Factor VIII inhibitors not exceeding 10 Bethesda Unit (BU) per milliliter (ml) E. Factor VIII Recombinate (ADAVATE, Helixate FS, Kogenate, Novoeight, Recombinate, Xyntha) are not medically necessary when the above criteria are not met and for all other indications including, but not limited to treatment of individuals with VWD V. Factor VIII (Recombinant), Porcine Sequence (Obizur) A. Factor (Recombinant), Porcine Sequence are medically necessary for the following: i. For treatment of bleeding episodes in adults with acquired hemophilia A B. Factor (Recombinant), Porcine Sequence (Obizur) are not medically necessary when the above criteria are not met and for all other indications including, but not limited to: i. Treatment of individuals with congenital hemophilia A with Factor VIII deficiency ii. Treatment of individuals with von Willebrand disease iii. Treatment of individuals with acquired hemophilia A and baseline anti-porcine Factor VIII inhibitor titer greater than 20 BU/ml VI. Factor VIII/von Willebrand Factor Complex (Alphanate, Humate-P, Wilate) A. Factor VIII/von Willebrand Factor Complex (Alphanate, Humate-P, Wilate) are medically necessary as treatment for individuals with von Willebrand disease (Type 1, 2 or unknown) when the following criteria are met (i alone OR ii & iii): i. VWD is severe OR ii. VWD is mild to moderate and use of desmopressin is known or suspected to be inadequate AND iii. Individual is being treated for either: 1. Spontaneous and trauma-induced bleeding episodes OR 2. Peri-procedural management for surgical, invasive or interventional radiology procedures B. Factor VIII/von Willebrand Factor Complex (Alphanate, Humate-P) is medically necessary for the following: i. For treatment of bleeding episodes in an individual with hemophilia A and Factor VIII deficiency C. Factor VIII/von Willebrand Factor Complex (Alphanate) is medically necessary for the following: i. For treatment of bleeding episodes in an individual with acquired Factor VIII deficiency D. Factor/von Willebrand Factor Complex (Alphanate, Humate-P, Wilate) is not medically necessary when the above criteria are not met and for any of the following: i. All other indications including, but not limited to prophylaxis therapy in individuals with VWD ii. Alphanate for individuals with severe VWD (Type 3) undergoing major surgery iii. Wilate for individuals with hemophilia A
4 Page 4 iv. Wilate for individuals with VWD when used as prevention of excessive bleeding during and after surgery VII. Coagulation Factor IX, Human plasma-derived (Alphanine SD, Mononine) A. Human plasma-derived coagulation Factor IX (Alphanine SD, Mononine) is medically necessary for the following: i. For treatment of bleeding episodes in an individual with hemophilia B and Factor IX deficiency B. Human plasma-derived coagulation Factor IX (Alphanine SD, Mononine) is not medically necessary when the above criteria are not met, including but not limited to the following: i. Treatment or reversal of coumarin-induced anticoagulation ii. Hemorrhagic state or coagulopathy associated with liver dysfunction iii. Treatment of individuals with hemophilia A with inhibitors to factor VIII iv. Replacement therapy of other clotting factors which include factors II, VII and X VIII. Factor IX Complex, Human plasma-derived (Bebulin, Profilnine SD) A. Human plasma-derived Factor IX complex (Bebulin, Profilnine SD) is medically necessary for the following: i. For treatment of bleeding episodes in an individual with hemophilia B (congenital factor IX deficiency or Christmas disease) B. Human plasma-derived Factor IX complex (Bebulin, Profilnine SD) is not medically necessary when the above criteria are not met and for all other indications including, but not limited to use for treatment of individuals with Factor VII deficiency IX. Factor IX Recombinant (Benefix, RIXUBIS) A. Recombinant coagulation Factor IX (Benefix, RIXUBUS) is medically necessary to treat individuals with hemophilia B (congenital factor IX deficiency or Christmas disease) when the following criteria are met: i. To treat bleeding episodes OR ii. For peri-procedural management for surgical, invasive or interventional radiology procedures B. Recombinant coagulation Factor IX (RIXUBIS) is medically necessary as routine prophylaxis to prevent or reduce the frequency of bleeding episodes when the following criteria are met (i alone OR ii & iii): i. Individual has severe hemophilia B (defined as less than or equal to 1 IU/dL or 1% endogenous Factor IX) OR ii. Individual has mild to moderate hemophilia B (defined as endogenous Factor IX less than or equal to 40 IU/dL [less than 40%], but greater than 1 IU/dL) AND iii. When the member has documented history of one of the following: 1. One or more episodes of spontaneous bleeding into joint OR 2. One or more episodes of spontaneous bleeding into the central nervous system OR 3. Four or more episodes of soft tissue bleeding in an eight week period C. Recombinant coagulation Factor IX (Benefix, RIXUBIS) is not medically necessary when the above criteria are not met and for all other indications including, but not limited to the following: i. Treatment of other factor deficiencies (for example factors II, VII, VIII and X) ii. Treatment of individuals with hemophilia A with inhibitors to factor VIII iii. To reverse coumarin-induced anticoagulation iv. Treatment of bleeding due to low levels of liver-dependent coagulation factors v. Benefix for routine prophylaxis to prevent or reduce the frequency of bleeding episodes vi. RIXUBIS for the induction of immune tolerance in individuals with hemophilia B X. Factor XIII (Corifact, TRETTEN) A. Human plasma-derived concentrate Factor XIII (Corifact) is medically necessary for individuals with Factor XIII deficiency for the following indications: i. As routine prophylactic treatment OR ii. Peri-procedural management for surgical, invasive or interventional radiology procedures for
5 Page 5 individuals with congenital Factor XIII deficiency B. Recombinant coagulation Factor XIII A-Subunit (TRETTEN) is medically necessary for the following: i. As routine prophylaxis for bleeding in individuals with congenital Factor XIII A-subunit deficiency C. Coagulation Factor XIII (Corifact, TRETTEN) is not medically necessary when the above criteria are not met and for all other indications including, but not limited to treatment of individuals with congenital Factor XIII B-subunit deficiency XI. Fibrinogen Concentrare, Human plasma-derived (RiaSTAP) A. Human plasma-derived fibrinogen concentrate (RiaSTAP) is medically necessary for the following: i. For the treatment of acute bleeding episodes in individuals with congenital fibrinogen deficiency (that is, afibrinogenemia or hypofibrinogenemia) B. Human plasma-derived fibrinogen concentrate (RiaSTAP) is not medically necessary when the above criteria are not met and for all other indications including, but not limited to treatment of individuals with dysfibrinogenemia. Renewal Criteria I. All renewals will be for six months if therapy determined to be effective and without significant adverse events References 1. Hoots W. Keith and Shapiro, Amy D, UpToDate July , Factor VIII and Factor IX Inhibitors in Patients with Hemophilia 2. Keating GM, Dhillon S. Octocog alfa (Advate ): a guide to its use in hemophilia A. BioDrugs Aug 1; 26(4): doi: / Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6): Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011; 9(4): National Hemophilia Foundation MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding) November 3, 2007, and adopted by the NHF Board of Directors on November 4, Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J, Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010; 149(4): Hermans C, De Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T, Lavigne-Lissalde G, Perez R, Richards M, Dolan G; European Haemophilia Therapy Standardisation Board. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011 May; 17(3): doi: /j x. Epub 2011 Feb Tuohy E, Litt E, Alikhan R. Treatment of patients with von Willebrand disease. J Blood Med. 2011;2: doi: /JBM.S9890. Epub 2011 Apr 20. Erratum in: J Blood Med May 20; 4: MASAC Recommendations Regarding the Treatment of Von Willebrand Disease Approved by the Medical and
6 Page 6 Scientific Advisory Council (MASAC) on April 18, 2010, and adopted by the NHF Board of Directors on June 26, Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia Nov; 17(6): Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant Factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level<1%) or moderately severe (FIX level?2%) haemophilia B. Haemophilia. 2014; 20(1): National Hemophilia Foundation, MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders, Revised October 2013 Available at Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia Jan; 20(1): Stasyshyn O, Antunes S, Mamonov V, Ye X, Epstein J, Xiong Y, Tangada S. Prophylaxis with antiinhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia Mar 3. doi: /hae [Epub ahead of print] 15. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012; 119(22): Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P, Fibrinogen Concentrate Study Group. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009; 7(12): 2064
7 Page 7 Section II Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL M Koate-DVI Monoclate-P ADVATE Helixate FS Kogenate FS Novoeight RECOMBINATE Xyntha Obizur Alphanate HUMATE-P Wilate AlphaNine SD Mononine BEBULIN Profilnine SD BeneFix RIXUBIS Corifact TRETTEN RiaSTAP Specify: 5. DIAGNOSIS:
8 Page 8 6. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY NOTE: Any areas not filled out are considered not applicable to your patient and MAY AFFECT THE OUTCOME of this request. FEIBA NF: Yes No Patient is using FEIBA NF to treat bleeding episodes and the patient has Hemophilia A or B Yes No Patient is using FEIBA NF as peri-procedural operative management for surgical, invasive or interventional radiology procedures and the patient has Hemophilia A or B Yes No Patient is using FEIBA NF as routine prophylaxis to prevent or reduce the frequency of bleeding episodes and the patient has Hemophilia A or B NovoSeven RT: Yes No Patient is using NovoSeven RT for treatment of bleeding episodes Yes No Patient is using NovoSeven RT for prevention of bleeding in surgical interventions or invasive procedures Yes No Patient is using NovoSeven RT to treat Glanzmann s thrombasthenia and a documented refractoriness to platelet transfusions with or without antibodies to platelets Yes No Does the patient have hemophilia A or B with inhibitors to Factor VIII or Factor IX; OR has the patient acquired hemophilia Yes No Does the patient have congenital Factor VII deficiency HEMOFIL M: Yes No Patient has hemophilia A and factor VIII deficiency and is using HEMOFIL M to treat bleeding episodes Koate-DVI OR Monoclate-P: Yes No Patient has hemophilia A and factor VIII deficiency and is using the request drug to treat bleeding episodes Yes No Patient has hemophilia A and factor VIII deficiency and is using the request drug as peri-procedural management for surgical, invasive or interventional radiology procedures ADVATE OR Novoeight: Yes No Patient has hemophilia A and factor VIII deficiency and is using the request drug to treat bleeding episodes Yes No Patient has hemophilia A and factor VIII deficiency and is using the request drug as peri-procedural management for surgical, invasive or interventional radiology procedures Yes No Patient is using request drug as routine prophylaxis to prevent or reduce the frequency of bleeding Episodes If Yes: Yes No Patient has severe hemophilia A (defined as less than or equal to 1 International Unit per deciliter [IU/dL] or 1% endogenous Factor VIII) Yes No Patient has mild to moderate hemophilia A (defined as endogenous Factor VIII less than or equal to 40 IU/dL [less than or equal to 40%], but greater than 1 IU) If Yes: Patient has a documented history of one of the following (please indicate): Yes Yes Yes No One or more episodes of spontaneous bleeding into joint No One or more episodes of spontaneous bleeding into the central nervous system No Four or more episodes of soft tissue bleeding in an eight week period
9 Page 9 Helixate FS: Yes No Patient has hemophilia A and factor VIII deficiency and is using Helixate FS to treat bleeding episodes Yes No Patient has hemophilia A and factor VIII deficiency and is using Helixate FS as peri-procedural management for surgical, invasive or interventional radiology procedures Yes No Helixate FS is being used as routine prophylaxis for a child (age 0-16 years) with hemophilia A and factor VIII deficiency to reduce the risk of joint damage in those without pre-existing joint damage Yes No Patient is using Helixate FS as routine prophylaxis to prevent or reduce the frequency of bleeding episodes If Yes: Yes No Patient has severe hemophilia A (defined as less than or equal to 1 International Unit per deciliter [IU/dL] or 1% endogenous Factor VIII) Yes No Patient has mild to moderate hemophilia A (defined as endogenous Factor VIII less than or equal to 40 IU/dL [less than or equal to 40%], but greater than 1 IU) If Yes: Patient has a documented history of one of the following (please indicate): Yes Yes Yes No One or more episodes of spontaneous bleeding into joint No One or more episodes of spontaneous bleeding into the central nervous system No Four or more episodes of soft tissue bleeding in an eight week period Kogenate FS: Yes No Patient has hemophilia A and factor VIII deficiency and is using Kogenate FS to treat bleeding episodes Yes No Patient has hemophilia A and Factor VIII deficiency and is using Kogenate FS for peri-procedural management for surgical, invasive or interventional radiology procedures Yes No Kogenate FS is being used for routine prophylaxis for a child (age 0-16 years) with hemophilia A and factor VIII deficiency to reduce the risk of joint damage in those without pre-existing joint damage RECOMBINATE: Yes No Patient has hemophilia A and factor VIII deficiency and is using RECOMBINATE to treat bleeding episodes Yes No Patient has hemophilia A and Factor VIII deficiency and is using RECOMBINATE for peri-procedural management for surgical, invasive or interventional radiology procedures Yes No Patient is using RECOMBINATE as treatment of acquired Factor VIII inhibitors not exceeding 10 Bethesda Unit (BU) per milliliter (ml) Xyntha: Yes No Patient has hemophilia A and factor VIII deficiency and is using Xyntha to treat bleeding episodes Yes No Patient has hemophilia A and Factor VIII deficiency and is using Xyntha for peri-procedural management for surgical, invasive or interventional radiology procedures Obizur: Yes No Patient is using Obizur for treatment of bleeding episodes in adults with acquired hemophilia A
10 Page 10 Alphanate: Yes No Patient has a diagnosis of von Willebrand disease (Type 1,2 or unknown) If Yes Yes No The patient has severe von Willebrand disease (VWD) Yes No The patient has mild to moderate von Willebrand disease (VWD) and use of desmopressin is known or suspected to be inadequate If Yes: The patient is being treated for (please indicate: Yes No Spontaneous and trauma-induced bleeding episodes Yes No Spontaneous Peri-procedural management for surgical, invasive or interventional radiology procedures Yes No The patient has hemophilia A and Factor VIII deficiency and is using Alphanate to treat bleeding episodes Yes No The patient has acquired Factor VIII deficiency and is using Alphanate to treat bleeding episodes HUMATE-P: Yes No Patient has a diagnosis of von Willebrand disease (Type 1, 2 or unknown) If Yes Yes No The patient has severe von Willebrand disease (VWD) Yes No The patient has mild to moderate von Willebrand disease (VWD) and use of desmopressin is known or suspected to be inadequate If Yes: The patient is being treated for (please indicate: Yes No Spontaneous and trauma-induced bleeding episodes Yes No Spontaneous Peri-procedural management for surgical, invasive or interventional radiology procedures Yes No The patient has hemophilia A and Factor VIII deficiency and is using HUMATE-P to treat bleeding episodes Wilate: Yes No Patient has a diagnosis of von Willebrand disease (Type 1, 2 or unknown) If Yes Yes No The patient has severe von Willebrand disease (VWD) Yes No The patient has mild to moderate von Willebrand disease (VWD) and use of desmopressin is known or suspected to be inadequate If Yes: The patient is being treated for (please indicate: Yes No Spontaneous and trauma-induced bleeding episodes Yes No Spontaneous Peri-procedural management for surgical, AlphaNine SD OR Mononine: invasive or interventional radiology procedures Yes No The patient has hemophilia B and Factor IX deficiency and is using requested drug to treat bleeding episodes BEBULIN OR Profilnine SD: Yes No The patient has hemophilia B (congenital factor IX deficiency or Christmas disease) and is using the requested drug to treat bleeding episodes BeneFix: Yes No The patient has hemophilia B (congenital factor IX deficiency or Christmas disease) and is using the requested drug to treat bleeding episodes Yes No The patient has hemophilia B (congenital factor IX deficiency or Christmas disease) and is using BeneFix as peri-procedural management for surgical, invasive or interventional radiology procedures
11 Page 11 RIXUBIS: Yes No The patient has hemophilia B (congenital factor IX deficiency or Christmas disease) and is using the requested drug to treat bleeding episodes Yes No The patient has hemophilia B (congenital factor IX deficiency or Christmas disease) and is using BeneFix as peri-procedural management for surgical, invasive or interventional radiology procedures Yes No Patient has severe hemophilia B (defined as less than or equal to 1 IU/dL or 1% endogenous Factor IX) and using RIXUBIS as routine prophylaxis to prevent or reduce the frequency of bleeding episodes Yes No Patient has mild to moderate hemophilia B (defined as endogenous Factor IX less than or equal to 40 IU/dL [less than 40% ], but greater than 1 IU/dL) and using RIXUBIS as routine prophylaxis to prevent or reduce the frequency of bleeding episodes If Yes: The patient has a documented history of one of the following (please indicate): Yes No One or more episodes of spontaneous bleeding into joint Yes No One or more episodes of spontaneous bleeding into the central nervous system Yes No Four or more episodes of soft tissue bleeding in an eight week period Corifact: Yes No Patient has Factor XIII deficiency and is using Corifact as routine prophylactic treatment Yes No Patient has congenital Factor XIII deficiency and is using Corifact as peri-procedural management for surgical, invasive or interventional radiology procedures TRETTEN: Yes No Patient has congenital Factor XIII A-subunit deficiency and is using TRETTEN for routine prophylaxis for bleeding RiaSTAP: Yes No Patient has congenital fibrinogen deficiency (that is, afibrinogenemia or hypofibrinogenemia) and is using RiaSTAP to treat acute bleeding episodes
12 Page 12 Section III Physician Information Physician Name National Provider Identification (NPI) Number Clinic Name Address (Street, City, State, Zip Code) Physician Telephone Number Physician Fax Number Physician Signature Date Section IV For WEA Trust Use Only Plan: Copay Tiers: Date of Receipt: Remarks: Approve Deny More information is needed Incomplete form Submission and review of this form does not guarantee approval of this request. Unless approved, payment of the brand-name medication will be limited to the amount the Trust would have paid for the generic equivalent. Insureds and providers will be informed of the decision in writing within approximately 30 days. Fax to: Pharmacy Services (608) Mail to: WEA Trust Pharmacy Services Prior Authorization PO Box Eagan, MN
Medication Prior Authorization Form
Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Clotting Factors and Antithrombin Effective Date... 4/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 8007 Table of Contents Coverage Policy...
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationQuarterly Pharmacy Formulary Change Notice
Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our December 18, 2014 Value Assessment Committee (VAC) meeting.
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at
More informationMedication Prior Authorization Form
Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationMethod of Viral Inactivation or Depletion. Generation/ Human or Animal Protein in Culture. Third/ None 1. Immunoaffinity
TABLE I. Products Licensed in the U.S. to Treat HEMOPHILIA A A. Recombinant FACTOR VIII Concentrates The table includes bioengineered recombinant factor concentrates with altered properties such as extended
More informationMedication Prior Authorization Form
Reclast (Zoledronic Acid) Policy Number: 1050 Policy History Approve Date: 12/11/2015 Revise Dates: 8/22/2016 Next Review: 12/11/2016 Review Dates: Preauthorization All Plans Benefit plans vary in coverage
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationRecombinant Treatments for Bleeding Disorders. An overview of treatments that are considered to have a low risk of viral transmission
Recombinant Treatments for Bleeding Disorders An overview of treatments that are considered to have a low risk of viral transmission History of bleeding disorder treatments Recombinant products: A significant
More informationQuick Reference: Plasma Protein Products
All plasma protein products a contraindicated in patients with any of the following: Hypersensitivity to the product or any ingdient in the formulation or component of the container. Pvious anaphylactic
More informationPeri-operative strategy in patients with congenital disorders of haemostasis
06RC1 - Filipescu Peri-operative strategy in patients with congenital disorders of haemostasis Daniela Filipescu Cardiac Anaesthesia and Intensive Care Medicine, Iliescu Emergency Cardiovascular Diseases
More informationStudy design: Multicenter, randomized, controlled, cross-over, blinded PK comparison
Brand Name 1, 2 : Rixubis Generic Name 1, 2 : Coagulation factor IX recombinant Manufacturer 5 : Baxter Drug Class 1, 2, 3 : Antihemophilic agent Labeled Uses 1, 2 : Hemophilia B hemorrhage, routine prophylaxis,
More informationClinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages)
Clinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages) NHS England Reference: 170105P 1 NHS England INFORMATION READER BOX Directorate Medical Operations
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (DDAVP Injection, Stimate) Reference Number: CP.PHAR.214 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Coding Implications Revision
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationMedication Prior Authorization Form
Policy Number: 1054 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationMark T. Reding, MD Associate Professor of Medicine Hematology, Oncology and Transplantation Division Director, Center for Bleeding and Clotting
Mark T. Reding, MD Associate Professor of Medicine Hematology, Oncology and Transplantation Division Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical School Minneapolis,
More informationClinical Policy: Desmopressin Acetate (DDAVP, Stimate, Noctiva) Reference Number: ERX.NPA.48 Effective Date:
Clinical Policy: (DDAVP, Stimate, Noctiva) Reference Number: ERX.NPA.48 Effective Date: 05.02.17 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCLINICAL GUIDE TO TRANSFUSION
Man-Chiu Poon, MD, MSc, FRCPC; M. Dawn Goodyear, MD, MSc, FRCPC; and Adrienne Lee, MD I. GENERAL PRINCIPLES Abnormal bleeding may result from defects in platelets, coagulation factors and/or blood vessels.
More informationClinical Policy: Desmopressin Acetate (DDAVP Injection) Reference Number: CP.PHAR.214
Clinical Policy: Acetate (DDAVP Injection) Reference Number: CP.PHAR.214 Effective Date: 05/16 Last Review Date: 05/17 See Important Reminder at the end of this policy for important regulatory and legal
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA)
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: European Plasma Fractionation Association (EPFA) 1. Summary
More informationMASAC RECOMMENDATIONS REGARDING RARE COAGULATION FACTOR DISORDERS
MASAC RECOMMENDATIONS REGARDING RARE COAGULATION FACTOR DISORDERS The following recommendations were approved by the Medical and Scientific Advisory Council (MASAC) on November 12, 2011, and adopted by
More informationORIGINAL ARTICLE Clinical haemophilia. Introduction
Haemophilia (2014), 20, 58 64 DOI: 10.1111/hae.12242 ORIGINAL ARTICLE Clinical haemophilia Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison
More informationDiagnosis and Management of Von Willebrand Disease
CLINICAL VIGNETTE Diagnosis and Management of Von Willebrand Disease Olga Olevsky, M.D. and Stephen Wong, M.D. Von Willebrand s Disease is the most common inherited bleeding disorder. Low levels of Von
More informationClinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages)
Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages) Reference: NHS England: 16042/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationAcquired Inhibitors of Coagulation
Acquired Inhibitors of Coagulation Christine L Kempton, MD, MSc Emory University Disclosures for In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research
More informationPeer Review Report #1. Desmopressin. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #1 Desmopressin (1) Does the application adequately address the issue of the public health need for the medicine? Desmopressin
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:
More informationClinical Commissioning Policy Proposition: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages)
Clinical Commissioning Policy Proposition: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages) Reference: NHS England 1717 Prepared by the National
More informationMedication Prior Authorization Form
Policy Number: 1055 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationInhibitors in Patients With Hemophilia Elena Santagostino MD, PhD
Inhibitors in Patients With Hemophilia Elena Santagostino MD, PhD Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione Ca Granda - Ospedale Maggiore Policlinico and University of Milan Milan,
More informationPLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL
PLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL http://www.ukhcdo.org UKHCDO protocol for first line immune tolerance induction for children with severe
More informationKeywords: bleeding, haemarthrosis, haemophilia, joint bleeding, pharmacokinetic-guided treatment, prophylaxis, rahf- PFM
Haemophilia (16), 22, 514 5 DOI:.1111/hae.1295 ORIGINAL ARTICLE Clinical haemophilia Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every
More informationHemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are the most
Pharmacotherapeutics Recent Advance of Pharmacotherapy in Hemophilia Young Shil Park, MD Department of Pediatrics, Kyunghee University College of Medicine E - mail : pysmd@khnmc.or,kr J Korean Med Assoc
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 March 2007 FACTANE 100 I.U. /ml, powder and solvent for solution for injection Box of 1 2.5 ml vial (CIP: 562 115-5)
More informationMedi-Cal DHCS Carve Out Medication List
Medi-Cal DHCS Carve Out Medication List The drugs shown below are non-capitated or carved-out of Managed Care Plans (MCPs). IE H P i s a man ag ed c a r e p l a n. T his means they are not reimbursed by
More informationProphylaxis & Arthropathy
Prophylaxis & Arthropathy On-Demand and Prophylaxis Treatment Coagulation factor replacement may be given when a bleed occurs (on-demand therapy) or before bleeding occurs, to prevent bleeds (prophylactic
More informationClinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages)
Clinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages) NHS England Reference: 170067/P NHS England INFORMATION READER BOX
More informationIdelvion. (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow
Idelvion (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow Introduction Brand name: Idelvion Generic name: Coagulation factor IX (recombinant), albumin fusion protein
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationThe First rfviii WITH A PROLONGED HALF-LIFE
Visit ELOCTATEpro.com for more information The First rfviii WITH A PROLONGED HALF-LIFE Indications ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic
More information2015 Comes to an End
SM www.bluechoicescmedicaid.com Volume 3, Issue 10 November December 2015 2015 Comes to an End It s hard to believe that 2015 has come and gone. The International Classification of Diseases, 10th Revision
More informationSession 1 : Fibrinogen deficiencies
13 th Workshop on Thrombosis and Paediatric Haemostasis Marseille, 13 th October 2010 Session 1 : Fibrinogen deficiencies Clinical, biological and therapeutic concerns : P De Moerloose, Geneva Genetic
More informationCoagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis
CADTH TECHNOLOGY REVIEW Coagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 1 Publication
More informationCommentary: Rapid Report Treatment of Hemophilia Patients
Schoenfelder T, Bleß HH. J Rare Dis Res & Treatment. (2016) 1(2): 1-7 www.rarediseasesjournal.com Journal of Rare Diseases Research & Treatment Commentary Open Access Commentary: Rapid Report Treatment
More informationChoicing therapeutic goals and accomplishing regimens
Choicing therapeutic goals and accomplishing regimens the purchaser the treating physician the resources the patient (and caregivers) the social tissue Identifying challenges and barriers Previous clinical
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationIntroduction. to that of unaffected individuals. 3 Indeed, the life expectancy. years between 1990 and
1 TABLE OF CONTENTS Introduction Case 1: Jose C. Clinical Discussion Case 2: Andrew P. Clinical Discussion Case 3: Chris W. Clinical Discussion Summary References Hemophilia Clinical Consults: Inhibitor
More informationA bs tr ac t. background Effective ways to prevent arthropathy in severe hemophilia are unknown.
The new england journal of medicine established in 1812 august 9, 2007 vol. 357 no. 6 Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia Marilyn J. Manco-Johnson,
More informationGuideline for the use of emicizumab for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Guideline for the use of emicizumab for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors. Guideline for the use of emicizumab for routine prophylaxis
More informationEuropean Medicines Agency decision
EMA/585994/2013 P/0270/2013 of 30 October 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for eptacog alfa (activated) (EMEA-001382-PIP01-12) in accordance with
More informationWhen should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow
When should I transfuse platelets and plasma for children? Dr Liz Chalmers Consultant Paediatric Haematologist Royal Hospital for Children Glasgow When should I transfuse platelets and plasma in children?
More informationTreatment of Patients with Haemophilia in China: Sub-analysis of the HERO study
Treatment of Patients with Haemophilia in China: Sub-analysis of the HERO study Baolai HUA Peking Union Medical College Hospital On behalf of Chinese HERO National Advisory Board 12-OCT-2013 Slide 1 Japanese
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationEasy bruising vs Coagulopathy
Easy bruising vs Coagulopathy Sept. 19, 2015 Lakehead Summer School Chris Hillis, MD MSc FRCPC hillis@hhsc.ca @HemeHillis Aim & Objectives Aim: To increase comfort in detecting non-pathologic bleeding
More informationPharmacoeconomics ЭФФЕКТИВНОСТИ ПРИ ОДОБРЕНИИ МЕДИЦИНСКИХ ТЕХНОЛОГИЙ ОХ ПОКУПАТЕЛЬНОЙ СПОСОБНОСТИ
Pharmacoeconomics co МЕТОДОЛОГИЧЕСКИЕ ОПРЕДЕЛЕНИЕ ПОРОГА ОСНОВЫ «ГОТОВНОСТИ АНАЛИЗА ПЛАТИТЬ» ЭФФЕКТИВНОСТИ ПРИ ОДОБРЕНИИ МЕДИЦИНСКИХ ТЕХНОЛОГИЙ ТЕХНОЛОГИЙ В УСЛОВИЯХ РОССИЙСКОГО ПРИ ПРОВЕДЕНИИ ЗДРАВООХРАНЕНИЯ,
More informationOpinion 2 April 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 2 April 2014 NOVOEIGHT 250 IU, powder and solvent for solution for injection B/1 vial of powder + 1 prefilled syringe
More informationThe Arrival of Longer Lasting Recombinant Products for Hemophilia. Steven Pipe, MD University of Michigan Ann Arbor, MI
Test The Arrival of Longer Lasting Recombinant Products for Hemophilia Steven Pipe, MD University of Michigan Ann Arbor, MI Disclosures for: Steven Pipe Conflict Research Support Director, Officer, Employee
More informationExperience with a third generation recombinant factor VIII concentrate (Advate Ò ) for immune tolerance induction in patients with haemophilia A
Haemophilia (2009), 15, 718 726 DOI: 10.1111/j.1365-2516.2008.01960.x ORIGINAL ARTICLE Inhibitors Experience with a third generation recombinant factor VIII concentrate (Advate Ò ) for immune tolerance
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationUK Standards of Care
UK Standards of Care Service Provision of Physiotherapy For Adults with Haemophilia & other Inherited Bleeding Disorders Page 1 of 10 Background Standards were originally written by the Haemophilia Chartered
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shima M, Hanabusa H, Taki M, et al. Factor VIII mimetic function
More informationVon Willebrand Disease: Management and Complications. Mike Makris Sheffield, UK
Von Willebrand Disease: Management and Complications Mike Makris Sheffield, UK Disclosures for Mike Makris Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationRoutine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
More informationContents 1 Bleeding disorders Haemophilia... 12
Contents 1 Bleeding disorders... 5 1.1 Features of a bleeding disorder... 5 1.2 First line diagnostic investigations... 5 1.2.1 Clotting screens... 6 1.3 Further investigations... 6 1.3.1 Investigation
More informationFactor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment
Haemophilia (2015), 1 10 DOI: 10.1111/hae.12621 ORIGINAL ARTICLE Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment S.
More informationMedication Prior Authorization Form
Remicade (Infliximab) Policy Number: 1051 Policy History Approve Date: 12/11/2015 Revise Dates: Next Review: 12/11/2016 Review Dates: Preauthorization All Plans Benefit plans vary in coverage and some
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationTreating breakthrough bleeds: A new approach
Treating breakthrough bleeds: A new approach Using Bypassing Agents With HEMLIBRA Prophylaxis Indication HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
More informationCoagulopathy Case - 3. Andy Nguyen, M.D. 2009
Coagulopathy Case - 3 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 21 year-old male seen in the emergency room with a swollen, tender right knee. Patient is an electrician who had fallen to the ground an
More informationGeneral approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013
General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding
More informationUK Standards of Care
UK Standards of Care Service Provision of Physiotherapy For Children with Haemophilia & other Inherited Bleeding Disorders Page 1 of 10 Background Standards were originally written by the Haemophilia Chartered
More informationHealthcare resource utilization among haemophilia A patients in the United States
Haemophilia (2012), 18, 332 338 DOI: 10.1111/j.1365-2516.2011.02677.x ORIGINAL ARTICLE Clinical haemophilia Healthcare resource utilization among haemophilia A patients in the United States L. A. VALENTINO,*
More informationGuidelines for Shared Care Centres and Community Staff
Reference: CG1410 Written by: Dr Jeanette Payne Peer reviewer Dr Jenny Welch Approved: February 2016 Approved by D&TC: 8th January 2016 Review Due: February 2019 Intended Audience This document contains
More informationClotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large healthcare database during
Journal of Thrombosis and Haemostasis, 13: 2168 2179 DOI: 10.1111/jth.13155 ORIGINAL ARTICLE Clotting factor product administration and same-day occurrence of thrombotic events, as recorded in a large
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationHemophilia care: Current guidelines and applications of new factor concentrates
Hemophilia care: Current guidelines and applications of new factor concentrates K Fischer MD PhD Van Creveldkliniek University Medical Center, Utrecht, The Netherlands Guidelines identified: WFH 2012 www.wfh.org
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationHemophilia is an X-linked hereditary blood
VOLUME 5 July - August 005 NUMBER 7-8 Original Article The prevalence of factor VIII in patients with severe hemophilia-a and its clinical characteristics Harijadi, MD; Djajadiman Gatot, MD; Arwin AP Akib,
More informationInhibitors in children and in adults Why they are different and what do they have common?
Inhibitors in children and in adults Why they are different and what do they have common? Jan Blatny, MD, PhD Petr Smejkal, MD, PhD Depts. of Paediatric/ Clinical Haematology Centre for Thrombosis and
More informationKulikov A.U., Babiy V.V. I.M. Sechenov First Moscow State Medical University, Moscow
IX НАЦИОНАЛЬНЫЙ КОНГРЕСС С МЕЖДУНАРОДНЫМ УЧАСТИЕМ «РАЗВИТИЕ ФАРМАКОЭКОНОМИКИ И ФАРМАКОЭПИДЕМИОЛОГИИ В РОССИЙСКОЙ ФЕДЕРАЦИИ» г.уфа, 16-17 МАРТА 2015 года ОРИГИНАЛЬНЫЕ РОССИЙСКИЕ ФАРМАКОЭКОНОМИЧЕСКИЕ ИССЛЕДОВАНИЯ
More informationLonoctocog Alfa: A Review in Haemophilia A
Drugs (2017) 77:1677 1686 DOI 10.1007/s40265-017-0815-0 ADIS DRUG EVALUATION Lonoctocog Alfa: A Review in Haemophilia A Zaina T. Al-Salama 1 Lesley J. Scott 1 Published online: 12 September 2017 Ó Springer
More informationAnita Shah 1 Alexander Solms. Verzhiniya Avramova 4 Stanislav Simeonov
Clin Pharmacokinet (207) 56:045 055 DOI 0.007/s40262-06-0492-2 ORIGINAL RESEARCH ARTICLE Improved Pharmacokinetics with Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationProperties of treatment options for hemophilia A and von Willebrand disease (VWD)
Properties of treatment options for hemophilia A and von Willebrand disease (VWD) ALPHANATE is the only FVIII/VWF complex to offer the convenience of a large 2000-IU vial size with low diluent volume Five
More informationIntroduction. Hemostatic therapy has evolved from whole blood to highly purified, virally inactive plasma-derived
1 TABLE OF CONTENTS Introduction Case 1: William M. Clinical Discussion Case 2: Marcus J. Clinical Discussion Case 3: Frank P. Clinical Discussion Summary References Hemophilia Clinical Consults: Therapeutic
More information